Industry: Animal Health
Animal health industry funding
Animal health investors back products with a clear licence route and a farmer or vet ready to pay. Waveup helps you prove both with your trial data, farm economics and likely partners.
- Market figures and investor lists covering vet medicines, diagnostics and livestock health
- Decks and models built around licensing steps, field trials and farm payback
- Waveup prepares investor materials for animal health companies: $3B+ raised for 600+ startups since 2014
In short
What is animal health industry funding?
Animal health industry funding is the capital raised by companies that make veterinary medicines, vaccines, diagnostics and livestock health tools. Angels, specialist VCs, corporate venture arms, private equity and grant programmes all provide it. The 20 largest animal health companies took in $38.6B in 2024. Most exits are a sale or licence to one of them.
- Who it's for
- Veterinary medicine, vaccine, diagnostics and livestock health companies, pre-seed to Series D+
- What we build
- Investor deck, financial model, valuation, investor list, data room
- Prices
- Deck from $6,000, model from $3,000. Flat fees
- Track record
- $3B+ raised for 600+ startups since 2014
Market data checked on 6 November 2026. Sources are under each section.
Why do investors back animal health in 2026?
Because disease keeps costing farmers money, and prevention is where sales grow. But the market is small and the buyers are few, so investors want proof early.
The opportunity
Outbreaks, food demand and pressure on antibiotics all create buyers for new products.
- Bird flu reached US dairy herds in 2024, and screwworm was confirmed in Texas and Arizona in October 2026
- USDA offered up to $100M for new screwworm tools through a Grand Challenge, now closed
- Elanco is launching a venture fund for pre-seed to Series A companies
The problem
Animal health is short of money. WOAH says it receives as little as 0.6% of global health spending.
Market size
How big is the animal health industry, and what drives it?
The 20 largest animal health companies took in $38.6B in 2024, S&P Global counts. Four forces shape where new money goes:
- Prevention: vaccines and parasiticides made up 60% of animal health sales in 2024
- Disease: animal diseases destroy more than 20% of global animal production each year
- Food demand: OECD and FAO expect poultry meat consumption to grow 21% by 2034
- Research: HealthforAnimals members invested $13.8B in R&D from 2020 to 2025
Venture capital
Is there venture money for animal health startups?
There is no public yearly total for animal health venture funding, and rounds are small. Money comes from agrifood funds, biotech investors and corporate venture arms, while the big animal health companies license and buy.
committed by Elanco over several years to Elanco Ventures, for pre-seed to Series A companies
of venture funding went into livestock health monitoring in the five years to 2025, Lux Research counts
paid by Merck in 2024 for Elanco's aqua business, with its fish vaccines and two plants
Who invests in animal health startups?
Animal health angels, agrifood VCs, life sciences funds, strategic buyers, private equity and US grants. One example of each; for more agriculture investors, see our list of agriculture venture capital firms.
Investor database
Agtech investors in our database
The funds with the most agtech investments. Pick a stage, or open a fund for its cheque sizes.
Top 5 by agtech investments
Investments by industry
- Agritech & Farming24%
- Software & Apps14%
- AI & Deep Tech11%
- Rounds
- SeedSeries ASeries BSeries C+
- Average cheque
- $500K–$1M$1M–$3M$3M–$10M
- Based in
- India
- Invests in
- South Asia
128 investments in total, 21 tagged Agritech & Farming.Open the full fund profile
Investments by industry
- Healthtech & Wellness25%
- Software & Apps23%
- Agritech & Farming12%
- Rounds
- SeedSeries ASeries BSeries C+
- Average cheque
- $1M–$3M$3M–$10M$10M–$50M
- Based in
- Chicago, USA
- Invests in
- USA
214 investments in total, 15 tagged Agritech & Farming.Open the full fund profile
Investments by industry
- Agritech & Farming17%
- Energy & Utilities14%
- Healthtech & Wellness11%
- Rounds
- SeedSeries ASeries BSeries C+
- Average cheque
- $500K–$1M$1M–$3M$3M–$10M
- Based in
- Chicago, United States
- Invests in
- USA
171 investments in total, 13 tagged Agritech & Farming.Open the full fund profile
Investments by industry
- Agritech & Farming20%
- Energy & Utilities18%
- CleanTech & Sustainability12%
- Rounds
- SeedSeries ASeries BSeries C+
- Average cheque
- $0–$100K$100K–$500K$500K–$1M
- Based in
- Beverly Hills, United States
- Invests in
- USA
27 investments in total, 10 tagged Agritech & Farming.Open the full fund profile
Investments by industry
- Agritech & Farming21%
- Software & Apps17%
- Hardware. Robotics & IoT14%
- Rounds
- Pre-seedSeedSeries A
- Average cheque
- $0–$100K$100K–$500K$500K–$1M$1M–$3M$3M–$10M
- Based in
- San Francisco, United States
- Invests in
- USA
126 investments in total, 9 tagged Agritech & Farming.Open the full fund profile
From our investor database.
What slows down an animal health raise?
Our Fundraising 2025 study asked 56 VCs why they turn founders down. Revenue growth, unit economics, burn and missed milestones led the list, with defensibility and crowded categories next. Animal health has its own version of each.
Small markets per product
Animal medicines are a niche next to human drugs. In Europe, they are worth about 3% of the human pharmaceutical market.
What investors ask
- How big can one product get, across species and countries?
What your deck shows
- Sales potential by species, country and buyer
- A platform that leads to a second product
Licences take years and cash
New medicines, vaccines and biologics need FDA, USDA or EMA approval before the first sale. BiomEdit raised about $18.4M in 2025 to carry it through USDA licensing and into launch.
What investors ask
- Which agency licenses your product, and when can you sell it?
What your deck shows
- Your licence route, step by step, with dates
- Cash to reach the licence and first sales
Farmers buy on payback
A livestock product sells only if it earns back its cost in growth, milk or lower losses. Products that cut the need for antibiotics lag: HealthforAnimals members delivered 19 of a planned 30 by 2025.
What investors ask
- After paying for your product, what does a farmer gain per animal?
What your deck shows
- Field-trial results in money per animal
- Your price against what farmers use today
Demand that follows outbreaks
An outbreak creates sudden demand, then policy decides who buys. Nearly 1,000 US dairy herds caught H5N1 bird flu between March 2024 and February 2025.
What investors ask
- Will sales hold up once the outbreak is under control?
What your deck shows
- Demand that doesn't rest on one outbreak
- Who pays: farmers, vets or governments
How we help you raise
Flat fees agreed before we start. No success fee on advisory work.
Licence route, field data and farm payback, in plain words.
Licensing costs, launch timing and sales by species, month by month.
A range set against animal health deals and licensing terms.
Agrifood funds, corporate venture arms and grants that fit your stage.
Trial data, regulatory files and manufacturing records, ready to review.
For a sale or licensing deal with an animal health company.
Who we are
Waveup is a London-based fundraising and growth advisory, working in 60+ countries and 90+ industries. Since 2014 we have built the decks, models, CIMs and valuations behind $3B+ raised for 600+ startups.
About usAnimal health industry funding FAQ
Who invests in animal health startups?
How do animal health startups get funding?
Who is the largest animal health company?
What do investors look for in an animal health startup?
How big is the animal health market?
How much does help with an animal health raise cost?
Industries we work with
Agriculture and Farming
- Agriculture and Farming
- AgTech
- Animal Health
- Vertical Farming
Related industries
Raising for an animal health company?
Send us your product, the species it serves and your next licensing step. We'll point out what investors are likely to test first.



